[Increase of the betazytotropic effect of intravenous arginine administration through glibenclamide in subjects with healthy metabolism and in patients with latent and manifest diabetes].
D000328:Adult; D000368:Aged; D001120:Arginine / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D003920:Diabetes Mellitus / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D005905:Glyburide / Q000494:pharmacology*; D006801:Humans; D007003:Hypoglycemia / Q000209:etiology; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000166:cytology / Q000187:drug effects*; D008297:Male; D008875:Middle Aged
D001786:Blood Glucose; D007328:Insulin; D001120:Arginine; D005905:Glyburide
Steigerung der betazytotropen Wirkung intravenöser Arginingaben durch Glibenclamid bei Stoffwechselgesunden und bei latenten und manifesten Diabetikern